This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
Integer Holdings Gains 40.8% YTD: What's Driving the Stock?
by Zacks Equity Research
ITGR shares gain on the back of growth in the Medical segment. However, fluctuations in the oil and energy market are concerning.
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
by Zacks Equity Research
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
by Zacks Equity Research
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
DGX vs. PNTG: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. PNTG: Which Stock Is the Better Value Option?
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
by Zacks Equity Research
Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform.
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
by Zacks Equity Research
Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
by Zacks Equity Research
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quarter performance.
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
by Zacks Equity Research
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
by Zacks Equity Research
Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
by Zacks Equity Research
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
by Zacks Equity Research
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
XRAY Q3 Earnings & Revenues Beat Estimates, 2024 Guidance Revised
by Zacks Equity Research
DENTSPLY SIRONA's third-quarter results showcase strong top-line growth in the Essential Dental Solutions segment. However, the lowered outlook for fiscal 2024 is a cause of concern.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket
by Zacks Equity Research
Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
by Zacks Equity Research
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.
Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y
by Zacks Equity Research
PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.